INTRODUCTION: Germ cell tumours (GCTs) of the testis show exquisite sensitivity to treatment with cisplatin. Despite the high cure rates provided by platinum-based chemotherapy, 10-20% of patients die from progressive disease. Although various cellular pathways may influence cisplatin efficacy, their actual impact has not been comprehensively investigated in advanced GCTs. The objective of the present study was to clarify the role of the expression status of proteins involved in the Rb and p53 tumour suppressor pathways in sensitivity and resistance of GCTs to cisplatin-based chemotherapy. MATERIALS AND METHODS: Paraffin-embedded tumour tissues from 84 patients with advanced GCT treated with cisplatin-based chemotherapy were analysed. Immunohistochemical expression of proteins p53 and mdm2, and the G1-phase cyclins D1 and D2 (CD1 and CD2) was assessed and correlated with the clinical course. RESULTS: The percentages of positive expression of p53, mdm2, CD1 and CD2 were 56, 57, 37.5 and 55%, respectively. From univariate analysis, there was no significant association between p53, mdm2 or CD1 expression and outcome. Instead, positive CD2 expression was found to be marginally associated with shorter median duration of progression-free survival (PFS) (p=0.06). In multivariate analysis, none of the molecular markers retained statistical significance with treatment response or survival. CONCLUSIONS: Tissular expression of p53, mdm2 and CD1 is not associated with prognosis or treatment response in patients with advanced GCT. Aberrant CD2 expression appears to further determine a shorter PFS. Larger and further studies are required to validate CD2 as a marker of cisplatin resistance.
INTRODUCTION:Germ cell tumours (GCTs) of the testis show exquisite sensitivity to treatment with cisplatin. Despite the high cure rates provided by platinum-based chemotherapy, 10-20% of patients die from progressive disease. Although various cellular pathways may influence cisplatin efficacy, their actual impact has not been comprehensively investigated in advanced GCTs. The objective of the present study was to clarify the role of the expression status of proteins involved in the Rb and p53tumour suppressor pathways in sensitivity and resistance of GCTs to cisplatin-based chemotherapy. MATERIALS AND METHODS:Paraffin-embedded tumour tissues from 84 patients with advanced GCT treated with cisplatin-based chemotherapy were analysed. Immunohistochemical expression of proteins p53 and mdm2, and the G1-phase cyclins D1 and D2 (CD1 and CD2) was assessed and correlated with the clinical course. RESULTS: The percentages of positive expression of p53, mdm2, CD1 and CD2 were 56, 57, 37.5 and 55%, respectively. From univariate analysis, there was no significant association between p53, mdm2 or CD1 expression and outcome. Instead, positive CD2 expression was found to be marginally associated with shorter median duration of progression-free survival (PFS) (p=0.06). In multivariate analysis, none of the molecular markers retained statistical significance with treatment response or survival. CONCLUSIONS: Tissular expression of p53, mdm2 and CD1 is not associated with prognosis or treatment response in patients with advanced GCT. Aberrant CD2 expression appears to further determine a shorter PFS. Larger and further studies are required to validate CD2 as a marker of cisplatin resistance.
Authors: P Mathijs Voorhoeve; Carlos le Sage; Mariette Schrier; Ad J M Gillis; Hans Stoop; Remco Nagel; Ying-Poi Liu; Josyanne van Duijse; Jarno Drost; Alexander Griekspoor; Eitan Zlotorynski; Norikazu Yabuta; Gabriella De Vita; Hiroshi Nojima; Leendert H J Looijenga; Reuven Agami Journal: Cell Date: 2006-03-24 Impact factor: 41.582
Authors: Elodie E Noel; Marc Yeste-Velasco; Xueying Mao; Jackie Perry; Sakunthala C Kudahetti; Ningfeng F Li; Swee Sharp; Tracy Chaplin; Liyan Xue; Alan McIntyre; Ling Shan; Thomas Powles; R Tim D Oliver; Bryan D Young; Janet Shipley; Daniel M Berney; Simon P Joel; Yong-Jie Lu Journal: Am J Pathol Date: 2010-04-15 Impact factor: 4.307
Authors: Khandan Keyomarsi; Susan L Tucker; Thomas A Buchholz; Matthew Callister; Ye Ding; Gabriel N Hortobagyi; Isabelle Bedrosian; Christopher Knickerbocker; Wendy Toyofuku; Michael Lowe; Thaddeus W Herliczek; Sarah S Bacus Journal: N Engl J Med Date: 2002-11-14 Impact factor: 91.245
Authors: Robyn Kukoski; Brian Blonigen; Ettore Macri; Andrew A Renshaw; Michael Hoffman; Massimo Loda; Milton W Datta Journal: Appl Immunohistochem Mol Morphol Date: 2003-06
Authors: Lara Grande; Gabriel Bretones; Manuel Rosa-Garrido; Eva M Garrido-Martin; Teresa Hernandez; Susana Fraile; Luisa Botella; Enrique de Alava; August Vidal; Xavier Garcia del Muro; Alberto Villanueva; M Dolores Delgado; Jose L Fernandez-Luna Journal: J Biol Chem Date: 2012-06-20 Impact factor: 5.157
Authors: Violeta Bakardjieva-Mihaylova; Karolina Skvarova Kramarzova; Martina Slamova; Michael Svaton; Katerina Rejlova; Marketa Zaliova; Alena Dobiasova; Karel Fiser; Jan Stuchly; Marek Grega; Blanka Rosova; Roman Zachoval; Petr Klezl; Vaclav Eis; Eva Kindlova; Tomas Buchler; Jan Trka; Ludmila Boublikova Journal: Cancers (Basel) Date: 2019-09-06 Impact factor: 6.639